Last reviewed · How we verify
Miltefosine Oral Capsule
At a glance
| Generic name | Miltefosine Oral Capsule |
|---|---|
| Also known as | Pentamidine isethionate inhaled, Cap. Miltefosine, topical miltefosine |
| Sponsor | Fundacion Nacional de Dermatologia |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Repurposing Ivermectin for PKDL Treatment (EARLY_PHASE1)
- A Clinical Trial to Investigate Efficacy, Safety and Pharmacokinetics (PK) of Two LXE408 Oral Regimens and Oral Miltefosine as Active Control in Participants Aged ≥ 18 Years Old With Localized Cutaneous Leishmaniasis in the Region of the Americas (AMR). (PHASE2)
- Randomised Clinical Trial for New Treatment Modalities for Cutaneous Leishmaniasis Caused by Leishmania Tropica, in Pakistan (PHASE3)
- Combination, Miltefosine Monotherapy for Cutaneous Leishmaniasis in New World (PHASE3)
- Treatment of Bolivian L Braziliensis Mucosal Leishmaniasis with Inhaled Pentamidine Plus Oral Miltefosine (PHASE2)
- Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa (PHASE3)
- Miltefosine and GM-CSF in Cutaneous Leishmaniasis (PHASE3)
- Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨ (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Miltefosine Oral Capsule CI brief — competitive landscape report
- Miltefosine Oral Capsule updates RSS · CI watch RSS
- Fundacion Nacional de Dermatologia portfolio CI